IL13RA2 and glioblastoma: Based on the demonstrated protective effects of GSK3 inhibition on activated T-cells, the authors of this study administered the IL-13Rα2 CAR T-cells and GSK3 inhibitor to mice bearing subcutaneous GBM xenografts and demonstrated that mice re-challenged with tumor after initial clearance did not develop new lesions.